309 related articles for article (PubMed ID: 34702122)
1. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis.
Wang X; Liu G; Chen S; Bi H; Xia F; Feng K; Ma K; Ni B
Int J Hyperthermia; 2021 Oct; 38(1):1519-1528. PubMed ID: 34702122
[TBL] [Abstract][Full Text] [Related]
2. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
[TBL] [Abstract][Full Text] [Related]
3. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection.
Feng Y; Wu H; Huang DQ; Xu C; Zheng H; Maeda M; Zhao X; Wang L; Xiao F; Lv H; Liu T; Qi J; Li J; Zhong N; Wang C; Feng H; Liang B; Ren W; Qin C; Nguyen MH; Zhu Q
Eur Radiol; 2020 Nov; 30(11):6357-6368. PubMed ID: 32529568
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis.
Li YC; Chen PH; Yeh JH; Hsiao P; Lo GH; Tan T; Cheng PN; Lin HY; Chen YS; Hsieh KC; Hsieh PM; Lin CW
BMC Gastroenterol; 2021 Nov; 21(1):418. PubMed ID: 34749663
[TBL] [Abstract][Full Text] [Related]
5. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma.
Endo K; Kuroda H; Oikawa T; Okada Y; Fujiwara Y; Abe T; Sato H; Sawara K; Takikawa Y
Scand J Gastroenterol; 2018 Dec; 53(12):1575-1583. PubMed ID: 30577723
[TBL] [Abstract][Full Text] [Related]
7. Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation and/or Transcatheter Arterial Chemoembolization: A Propensity Score-Matched Analysis.
Orimo T; Kamiyama T; Yokoo H; Wakayama K; Shimada S; Einama T; Kamachi H; Taketomi A
Dig Surg; 2018; 35(5):427-434. PubMed ID: 28903105
[TBL] [Abstract][Full Text] [Related]
8. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
9. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion.
Peng Z; Wu X; Li J; Pang H; Zhang Y; Lin M; Wang Z; Xiao H; Li B; Chen M; Feng S; Kuang M; Chen S
Int J Hyperthermia; 2022; 39(1):688-696. PubMed ID: 35469522
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance.
Cao S; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J; Zou Y
Cancer Imaging; 2022 Jan; 22(1):2. PubMed ID: 34983650
[TBL] [Abstract][Full Text] [Related]
11. Repeat hepatectomy versus radiofrequency ablation in management of recurrent hepatocellular carcinoma: an average treatment effect analysis.
Chua DW; Koh YX; Syn NL; Chuan TY; Yao TJ; Lee SY; Goh BKP; Cheow PC; Chung AY; Chan CY
Ann Surg Oncol; 2021 Nov; 28(12):7731-7740. PubMed ID: 33969464
[TBL] [Abstract][Full Text] [Related]
12. Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study.
Kim JG; Cho SK; Hyun D; Shin SW; Park KB; Park HS; Choo SW; Do YS; Woo SY; Baek SY
Abdom Radiol (NY); 2021 Dec; 46(12):5735-5745. PubMed ID: 34581928
[TBL] [Abstract][Full Text] [Related]
13. The risk factors for long-term survival outcome in solitary hepatocellular carcinoma up to 2 cm: Propensity score matching analysis in a population cohort with a high rate of HBV infection.
Wang G; Zhang W; Tan Y; Jiang L; Yang J; Yang J; Yan L
Int J Surg; 2019 Dec; 72():1-6. PubMed ID: 31610283
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
Zhou Q; Wang X; Li R; Wang C; Wang J; Xie X; Li Y; Li S; Mao X; Liang P
J Gastroenterol; 2022 Sep; 57(9):684-694. PubMed ID: 35816221
[TBL] [Abstract][Full Text] [Related]
16. Suppression of Local Tumor Progression in Perivascular Hepatocellular Carcinoma by Combination Therapy with Radiofrequency Ablation and Percutaneous Ethanol Injection: A Propensity Score Matching Analysis.
Takata K; Tanaka T; Anan A; Fukunaga A; Nagata T; Fukuda H; Yamauchi R; Kunimoto H; Yokoyama K; Morihara D; Takeyama Y; Iwata K; Shakado S; Sakisaka S; Hirai F
Oncology; 2022; 100(6):303-312. PubMed ID: 35114665
[TBL] [Abstract][Full Text] [Related]
17. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation.
Wang X; Liang H; Lu Z
Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044
[No Abstract] [Full Text] [Related]
19. Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis.
An C; Li WZ; Huang ZM; Yu XL; Han YZ; Liu FY; Wu SS; Yu J; Liang P; Huang J
Eur Radiol; 2021 Jul; 31(7):4764-4773. PubMed ID: 33399908
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
